PlainPill

Nalt

People mainly take Nalt for mood, focus, energy. Based on 50 first-hand reports and 0 meta-analyses & systematic reviews in the medical literature. Ranked #280 of 1,974 overall.

36
User score
Mostly positive
28% positive2% mixed4% negative66% unclear

Of reports that state an outcome, 82% are positive.

Clinical research
CLimited research
0
meta-analyses
1
RCTs
423
papers

What Nalt does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

CLimited research

1–4 randomized controlled trials, no meta-analysis yet. The grade measures how much human research exists — read the conclusions below for what it found.

No meta-analyses or systematic reviews published yet — 1 randomized trials found.

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

2x dailyas reported
frequentas reported
every 4 daysas reported
500mgas reported
1-2x/weekas reported
500 mg5 days on, 2 off

Reported side effects

How often each side effect came up across all reports.

sleep disruption ×1overstimulation when ×1tolerance ×1

What users say

Verbatim quotes, shortened only — each links to the original discussion.

“Sometimes I take NALT but I don't know if it helps.”
Source discussion ↗
“I struggle daily unless I take NALT (twice a day) and lion's mane”
Source discussion ↗
“I also take the following Nootropics: Lion's Mane, Bacopa, NALT, ALCAR, Alpha GPC and Citicoline, Rhodiola, Ginkgo, and Panax Ginseng. However, I still feel extremely tired”
Source discussion ↗
“NALT is one I like for short term boosts.”
Source discussion ↗
“Nalt I use fairly frequently for an alertness/mood boost.”
Source discussion ↗
Top discussions (5)

Other options for mood

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 2, 2026. How we rate